November 8, 2021 7:44am

Remember, patience is a virtue not an investment factor

Earnings: Editas Medicine (EDIT) on 11/8, Vericel (VCEL) and Applied Genetic Technologies (AGTC) on 11/9, BioLife Solutions BLFS) on 11/11

Pre-open indications: swapping actions, 1 SELL, 4 BUYs with 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.18% (+66 points), S&P futures are UP +0.06% (3 points) and NASDAQ futures are up +-0.01% (-2 point)

 

Stock futures are up yet, weak in early trading on Monday,

European stocks were fractionally flat

Asia-Pacific stocks were mixed after China’s trade data was released

  • Official data released over the weekend showed China’s exports surging 27.1% in October compared to a year ago. That was higher than the 24.5% growth forecast by analysts in a Reuters poll.

 

Henry’omics:

The three major U.S. stock averages each closed at record highs Friday to cap off a winning week.

 

Title explanation: Skip to My (The) Lou" is a popular American partner-stealing dance from the 1840s. ... and Alan Lomax wrote that "Skip to My Lou" was a simple game of stealing partners (or swapping partners as in square dancing). From ups to downs and BUYs from Sells and then do the opposite!

 

Earnings Results:

Editas Medicine (EDIT) a Q3 net off of -$391 m, a negative -0.57 per share, $657 m in cash, a runway until 2023 m while revenues came in at $6.2 m versus $62.8 m in Q3/20.

 

Economic data Docket: The producer price index and consumer price index are slated for release on Tuesday and Wednesday

 

If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Friday’s evening’s recap: “bag and tag ‘em, as LPS (loss-per-share) earnings define the week’s share pricing endings. Q3 earnings of net losses and revenues mostly lag estimates.” …  https://www.regmedinvestors.com/articles/12171

Q4: November, 3 positive and 2 negative close to date

  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL with a Pump or no promote:

Biostage (BSTG) closed flat again at $2.60Friday with 9,003 shares traded after Thursday’s flat with 82 shares traded, Wednesday’s -$0.40 to $2.60 with 1,208 shares traded, Tuesday’s -$0.10 to $3.00 with 200 shares traded following Monday’s flat again with 80 shares traded and the previous Friday’s flat with 95 shares traded.

  • What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.

Probabilities versus aftermarket/pre-open share pricing indication moves:

BUY:

Alnylam Pharmaceuticals (ALNY) closed +$1.70 after Thursdays +$12.68 with a pre-market of +$1.75 or +0.93%,

Editas Medicine (EDIT) closed down again -$0.34 after Thursday’s -$0.85 with NLS (net -loss-per-share) earnings with an aftermarket of +$0.91 or +2.43%

Intellia Therapeutics (NTLA) closed up +$1.54 after Thursday’s -$1.97 with a pre-market of +$0.52 or +0.38% earnings,

Sage Therapeutics (SAGE) closed down -$1.53 after Thursday’s -$0.44 with a pre-market of +$0.34 or +0.75%

 

SELL
uniQure NV (QURE) closed down -$0.78 after Thursday’s +$0.11 with a pre-market of -$0.13 or -0.37%,

 

The BOTTOM LINE: “I am still building a cash reservoir for I believe this market and sector is about to take a dive!”

It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.

We are seeing to date, one (1) net income – Bellicum Pharmaceuticals (BLCM),

  • Twenty-two (22) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager therapeutics (VYGR), Solid Biosciences (SLDB) and Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE) and Sangamo Therapeutics (SGMO) >and today’s Editas Medicine (EDIT)

… earning’s releases that initiated Q3 earnings reporting season and beginning the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

The stem, cell and gene therapy earnings with, Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.